Overexpression of PD-L1, the ligand for PD-1, is associated with decreased cytotoxic T cell activity, elevated tumorigenesis, and enhanced tumor invasiveness, all of which can be countered by anti-PD-L1 monoclonal antibody therapy (Shui et al. 2020). The gene discussed is PDCD1; the disease is neoplasm.